The patient’s genetic profile, including a CHEK2 mutation, HER-2 positivity, and a KRAS mutation, significantly impacts the behavior of colorectal adenocarcinoma and its response to treatment. This evidence concerns the gene ERBB2 and colorectal adenocarcinoma.